HTF Market Intelligence released a new research report of 499 pages on title ‘PharmaPoint: Hepatitis C Virus (HCV) Therapeutics – Global Drug Forecast and Market Analysis to 2025’ with detailed analysis, forecast and strategies.
The hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections of the liver and, if left untreated, can result in fibrosis, permanent liver damage (cirrhosis), HCC, and eventually death. A member of the Flaviviridae viral family and hepacivirus genus, HCV can be classified into six major genotypes, with many additional subtypes within each genotype. While genotype 1 (GT1) causes almost half of HCV infections, all six major genotypes (GT1-6) are prevalent worldwide. The genetic diversity of HCV strains, even within the same host, originates from the low fidelity of the ribonucleic acid (RNA) polymerase, and is thought to account for viral resistance when HCV is treated with a single drug.
During the last few years, the hepatitis C treatment landscape has experienced successive waves of revolutionary change, and is now dominated by high-performance regimens comprising a new generation direct acting antivirals (DAAs). The treatment arsenal has rapidly expanded from only one unsatisfactory option-peginterferon plus ribavirin-to a collection of combination and fixed-dose combination regimens that can cure most patients in as little as 8?12 weeks, many without the use of interferon and/or ribavirin. Currently, these interferon-free and interferon-sparing DAA regimens dominate the treatment landscape as they combine a very high cure rate with improved tolerability and simplified dosing.
Request a sample report @ https://www.htfmarketreport.com/sample-report/304235-pharmapoint-hepatitis-c-virus
Key Questions Answered
– Based on interviews with key opinion leaders (KOLs), GlobalData has identified key unmet needs in the hepatitis C marketplace.
– What will be the effect of recent and upcoming approval of pan-genotypic DAA regimens?
– How will patient populations develop with changing treatment rates and high cure rates?
– What research and development (R&D) strategies will companies leverage to compete in the future hepatitis C marketplace?
– Which patient population(s) are most likely to be targeted by upcoming pan-genotypic DAA treatment algorithms?
– We estimates that drug sales for hepatitis C in 2015 were approximately $21.7 billion across the 9MM. The global hepatitis C market is expected to experience a steady decline during the forecast period resulting in total sales of $17.5 billion by 2025, translating into a negative Compound Annual Growth Rate (CAGR) of 2.1%. The decline in sales will be most prominent in the US and in France, Germany, and the UK, while the southern European countries, Spain and Italy, as well as China, will see constant or even increasing market sizes during the forecast period.
– The launch of multiple pan-genotypic DAA regimens will provide improved efficacy profiles for difficult-to-treat patients, including patients infected with genotype 3 (GT3), individuals with renal failure, and patients with decompensated liver cirrhosis.
– The main barrier of future growth of the global HCV market will originate from the declining prevalence rates in most countries. Driven by modest treatment rates and excellent cure rates, the patient pools in most countries will steadily decline throughout the forecast; several markets will see significantly reduced total patient pools by 2025.
– Overview of hepatitis C infections, including epidemiology, etiology, pathophysiology, regional genotype distribution, as well current routine treatment recommendations of all 9MM covered.
– Topline hepatitis C market revenue from 2015-2025. Recent acquisitions, approvals and governmental recommendations and restrictions are included in the forecast model.
– Key topics covered include dynamics in the number of prevalent cases during the forecast, market characterization, unmet needs, and company strategies.
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
– Analysis of the current and future market competition in the global hepatitis C marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Companies Mentioned in the Report
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=304235
Table of Contents
1 Table of Contents 11
1.1 List of Tables 18
1.2 List of Figures 25
2 Introduction 28
2.1 Catalyst 28
2.2 Related Reports 29
2.3 Upcoming Related Reports 29
3 Disease Overview 30
3.1 Etiology and Pathophysiology 31
3.1.1 Etiology 31
3.1.2 Pathophysiology 34
3.2 Symptoms 35
3.3 Prognosis and Quality of Life 36
4 Epidemiology 38
4.1 Disease Background 38
4.2 Risk Factors and Comorbidities 39
4.3 Global Trends 41
4.3.1 Diagnosed Incidence and Total Prevalence 42
4.3.2 Genotype 48
4.4 Forecast Methodology 48
4.4.1 Sources Used Tables 50
4.4.2 Forecast Assumptions and Methods 60
4.4.3 Sources Not Used 81
4.5 Epidemiological Forecast of HCV (2015-2025) 82
4.5.1 Total Prevalent Cases 82
4.5.2 Diagnosed Prevalent Cases 98
4.6 Discussion 113
4.6.1 Epidemiological Forecast Insight 113
4.6.2 Limitations of the Analysis 114
4.6.3 Strengths of the Analysis 115
5 Disease Management 117
5.1 Diagnosis Overview 117
5.1.1 Initial Diagnosis and Referral 117
5.1.2 Patient Assessment 118
5.1.3 Viral Assessment 119
5.2 Treatment Guildines 120
5.3 US 124
5.3.1 Diagnosis 125
5.3.2 Treatment Guidelines 126
5.3.3 Clinical Practice and Coverage 129
5.4 5EU 133
5.4.1 Diagnosis Overview 134
5.4.2 Treatment Guidelines Overview 134
5.5 France 137
5.5.1 Diagnosis 137
5.5.2 Clinical Practice 138
5.6 Germany 139
5.6.1 Diagnosis 139
5.6.2 Clinical Practice 139
5.7 Italy 140
5.7.1 Diagnosis 140
5.7.2 Clinical Practice 140
5.8 Spain 141
5.8.1 Diagnosis 141
5.8.2 Clinical Practice 142
5.9 UK 142
5.9.1 Diagnosis 142
5.9.2 Clinical Practice 143
5.10 Japan 145
5.10.1 Diagnosis 145
5.10.2 Clinical Practice 146
5.11 Brazil 148
5.11.1 Diagnosis 149
5.11.2 Clinical Practice 149
5.12 China 150
5.12.1 Diagnosis 151
5.12.2 Clinical Practice 152
6 Competitive Assessment 155
6.1 Overview 155
6.2 Strategic Competitor Assessment 158
6.3 Major Brands – Fixed-Dose Combination Direct-Acting Antivirals 161
6.3.1 Harvoni (Ledipasvir/Sofosbuvir) 161
6.3.2 Viekira Pak (Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir) and Technivie (Ombitasvir/Paritaprevir/Ritonavir) 173
6.3.3 Zepatier (Elbasvir/Grazoprevir) 187
6.3.4 Epclusa (Sofosbuvir/Velpatasvir) 198
6.4 Major Brands – Single Component Direct-Acting Antivirals 209
6.4.1 Sovaldi (Sofosbuvir) 209
6.4.2 Daklinza (Daclatasvir) 218
6.4.3 Olysio (Simeprevir) 228
6.5 Major Brands – Peginterferon and Ribavirin 238
6.5.1 Pegasys (Peginterferon alfa-2a) and PegIntron (Peginterferon alfa-2b) 238
6.5.2 Copegus, Rebetol, and Generic Ribavirin 247
6.6 Other Branded Direct-Acting Antivirals 251
6.6.1 Incivek (Telaprevir) and Victrelis (Boceprevir) 252
6.6.2 Sunvepra (Asunaprevir) 254
6.6.3 Exviera (Dasabuvir) 254
6.6.4 Vanihep (Vaniprevir) 255
7 Unmet Needs and Opportunity Analysis 256…..View Detailed Table of Content @ https://www.htfmarketreport.com/reports/304235-pharmapoint-hepatitis-c-virus
Reasons to buy
The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the global hepatitis C market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the hepatitis C market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Make an enquiry before buying this Report @ https://www.htfmarketreport.com/enquiry-before-buy/304235-pharmapoint-hepatitis-c-virus
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218